Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT07948993

VOSE vs. MOSE in EUS-FNB for Pancreatic Masses

Conditions: Pancreatic Neoplasms

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 472
Sponsor: Ruijin Hospital

Location: Ruijin hospital Shanghai Shanghai Municipality

Summary

The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.

Eligibility Criteria

Inclusion Criteria: * Age above 18 years, male or female. * Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes. * Provision of signed written informed consent. Exclusion Criteria: * Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases. * Coagulation disorders (International Normalized Ratio \[INR\] ≥ 1.5, platelet count ≤ 50 × 10\^9/L) or current use of anticoagulant or antiplatelet medications. * Confirmed or suspected pregnancy. * Pathological diagnosis has already been established by other methods. * Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment. * Any other conditions that preclude the performance of EUS-FNB.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07948993). StuddyBuddy aggregates publicly available trial information.